4D Molecular Therapeutics (FDMT) Return on Sales Growth (3y) (2023 - 2026)

4D Molecular Therapeutics (FDMT) Return on Sales Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS Growth (3y) (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 1.00
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 0.00
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 0.00
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 0.00
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 4D Molecular Therapeutics 691.54 Mn 300.64 Mn - 134.00

Historic Data

Download Data
DateValue
Mar 31, 2026 134.00
Dec 31, 2025 24.00
Sep 30, 2025 -860.00
Jun 30, 2025 -5,781.00
Mar 31, 2025 -3,504.00
Dec 31, 2024 -50,264.00
Sep 30, 2024 -25,950.00
Jun 30, 2024 -9,089.00
Mar 31, 2024 -1,374.00
Dec 31, 2023 1,749.00
Sep 30, 2023 0.00
Jun 30, 2023 -210.00
Mar 31, 2023 -162.00